Today a very interesting article was published in Nature, focusing on the very promising results towards prevention of breast cancer. According to this study performed by Australian researchers, a cell-population with active RANKL signalling was characterized as the origin of cancerous cells. An already existing drug, denosumab, which inhibits the RANKL signalling, showed decreased cellular proliferation in breast biopsies of BRCA1 positive patients. This could be the beginning of a new preventive measure against breast cancer for woman carrying the BRCA1 mutation.
Click here to read the article.